<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="da32cfc3-eab8-41a8-a53e-9969ad200c8f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. <br/>
      <br/> VYVGART HYTRULO<sup>Â®</sup> (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use <br/> Initial U.S. Approval:  2023 </title>
   <effectiveTime value="20250414"/>
   <setId root="7104d9e5-9910-47f5-9a93-741ac50f43b6"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116702819" root="1.3.6.1.4.1.519.1"/>
            <name>argenx US</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="434078638" root="1.3.6.1.4.1.519.1"/>
                        <name>Patheon Italia SpA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-3102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="936939342" root="1.3.6.1.4.1.519.1"/>
                        <name>Lonza Biologics Tuas Pte.Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-3102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="042535740" root="1.3.6.1.4.1.519.1"/>
                        <name>Avid Bioservices Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-3102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-1221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="316126754" root="1.3.6.1.4.1.519.1"/>
                        <name>Vetter RVS</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-1221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="093149750" root="1.3.6.1.4.1.519.1"/>
                        <name>Lonza Biologics Portsmouth</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-1221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="172209277" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Indiana, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-3102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73475-1221" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="7381dfbc-cafc-4af9-8285-2369a4ee68c2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73475-3102" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VYVGART Hytrulo</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>efgartigimod alfa and hyaluronidase (human recombinant)</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="180" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="961YV2O515" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EFGARTIGIMOD ALFA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="961YV2O515" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EFGARTIGIMOD ALFA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2000" unit="U"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="743QUY4VD8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYALURONIDASE (HUMAN RECOMBINANT)</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="743QUY4VD8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYALURONIDASE (HUMAN RECOMBINANT)</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.4" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1D5Q932XM6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE MONOHYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>methionine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.4" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="5.8" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="20.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sucrose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5.6" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73475-3102-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230620"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102839" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 6: Drug/Biologic Combination" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761304" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230620"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73475-1221" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VYVGART Hytrulo</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>efgartigimod alfa and hyaluronidase (human recombinant)</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="961YV2O515" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EFGARTIGIMOD ALFA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="961YV2O515" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EFGARTIGIMOD ALFA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2000" unit="U"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="743QUY4VD8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYALURONIDASE (HUMAN RECOMBINANT)</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="743QUY4VD8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYALURONIDASE (HUMAN RECOMBINANT)</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="10.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F7LTH1E20Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.4" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1D5Q932XM6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE MONOHYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>methionine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.4" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="4.1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="20.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sucrose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73475-1221-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="4" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73475-1221-4" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250410"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761304" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250410"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="47440da3-d2ee-46a2-94cc-6795635940e2"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>6/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>)</td>
                                 <td>8/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.1">5.1</linkHtml>)</td>
                                 <td>8/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="b1313fd0-02fd-482d-9eca-5bdddb2ca180"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>VYVGART HYTRULO is indicated for the treatment of adult patients with:</paragraph>
                  <list listType="unordered">
                     <item>generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive</item>
                     <item>
                        <content styleCode="xmChange">chronic inflammatory demyelinating polyneuropathy (CIDP)</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with:</paragraph>
                        <list listType="unordered">
                           <item>generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive (<linkHtml href="#S1">1</linkHtml>)</item>
                           <item>chronic inflammatory demyelinating polyneuropathy (CIDP) (<linkHtml href="#S1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="5f484df6-16f9-4376-97d6-e97316135421"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>See Full Prescribing Information for instructions on dosage, preparation, and administration. (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>)</item>
                           <item>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Important Administration Information<list listType="unordered" styleCode="Circle">
                                 <item>VYVGART HYTRULO is for subcutaneous use only. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                 <item>Prefilled syringe can be administered by patients and/or caregivers. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                 <item>Vial to be administered with a winged infusion set by a healthcare professional only. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                              </list>
                           </item>
                           <item>gMG: recommended dose and dose schedule<list listType="unordered" styleCode="Circle">
                                 <item>Administer  in cycles of once weekly injections for 4 weeks. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                                 <item>Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                                 <item>Vial: 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase over 30 to 90 seconds. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                                 <item>Administer subsequent treatment cycles based on clinical evaluation;  safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                              </list>
                           </item>
                           <item>CIDP: recommended dose and dose schedule<list listType="unordered" styleCode="Circle">
                                 <item>Administer as once weekly injections. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                                 <item>Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over approximately 20 to 30 seconds. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                                 <item>Vial: 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase over 30 to 90 seconds. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="6b1daee4-8d86-4d9a-aca2-c50200638ad5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Vaccination</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. Because VYVGART HYTRULO causes transient reduction in IgG levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="3612aa3e-5d38-4680-97f2-3fa5ee3a4cc7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Important Dosage and Administration Instructions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">VYVGART HYTRULO is for subcutaneous use only. Do not administer intravenously. Do not dilute VYVGART HYTRULO.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="41dc0eb7-65d1-4023-8482-24b7d9eb63c8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Prefilled Syringe</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique <content styleCode="italics">[see <linkHtml href="#IFU">Instructions for Use</linkHtml>]</content>.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4093969a-790c-46f3-97b6-1ca493d0c42b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Vial</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">VYVGART HYTRULO vial is to be administered with a winged infusion set by a healthcare professional only <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="53013d1a-1631-4c6c-a8e5-ff1c81fa3ed5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Recommended Dosage for gMG</title>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="1bb132ad-701c-410d-8154-d8332e38cd00"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Prefilled Syringe</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 to 30 seconds in cycles of once weekly injections for 4 weeks.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9ec6ac1b-b09f-4f5f-a7e6-3532a325b526"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Vial</content>
                                 </content>
                              </paragraph>
                              <paragraph>The recommended dosage of VYVGART HYTRULO vial is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e7367711-da83-4e0d-b2e3-7588f9219e9f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General Dosage Considerations</content>
                              </paragraph>
                              <paragraph>Administer subsequent treatment cycles according to clinical evaluation. The safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.</paragraph>
                              <paragraph>If a scheduled dose is missed, VYVGART HYTRULO may be administered up to 3 days after the scheduled time point. Thereafter, resume the original dosing schedule until the treatment cycle is completed.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="1ef1e6a5-5576-4f2d-80de-c2680b450310"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Recommended Dosage for CIDP</title>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="3408626d-8af7-4003-8f11-3f8d9a4586de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Prefilled Syringe</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 to 30 seconds as once weekly injections.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0c88b6af-04da-4043-9ff0-c1b92a8106a5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Vial</content>
                                 </content>
                              </paragraph>
                              <paragraph>The recommended dosage of VYVGART HYTRULO vial is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 to 90 seconds as once weekly injections. </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5be95b7e-2494-421c-b62c-0d4f08b29b99"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General Dosage Considerations</content>
                              </paragraph>
                              <paragraph>											If a scheduled injection is missed, VYVGART HYTRULO may be administered up to 3 days after the scheduled time point. Thereafter, resume the original dosing schedule. 										</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="a157ff78-5c30-4a2e-ab14-f91fe6d96769"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5  Preparation and Administration Instructions</title>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="d1c07737-e93a-433f-a91a-7ea10944aebc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Single-Dose Prefilled Syringe</content>
                                 </content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="xmChange">Take the VYVGART HYTRULO prefilled syringe out of the refrigerator at least 30 minutes before injecting to allow it to reach room temperature <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>. Do not use external heat sources to bring the syringe to room temperature.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Visually inspect that the prefilled syringe solution is yellowish, clear to opalescent and devoid of particulate matter. Do not use if visible particles are present.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Each prefilled syringe is for one-time use only.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">To administer VYVGART HYTRULO prefilled syringe, use a safety needle that is 25G, 5/8 inches in length, and thin wall type. The safety needle is not included in the carton.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Choose an injection site on the abdomen (at least 2 inches away from the navel).</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="xmChange">Do not inject on areas where the skin is irritated, red, bruised, infected, tender, hard, or into areas where there are moles or scars.</content>
                                       </item>
                                       <item>
                                          <content styleCode="xmChange">Rotate injection sites for subsequent administrations.</content>
                                       </item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Inject VYVGART HYTRULO prefilled syringe subcutaneously into a pinched skin area at an angle of 45 to 90 degrees for approximately 20 to 30 seconds.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Discard any unused portions of medicine remaining in the syringe.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Localized injection site reactions may occur after VYVGART HYTRULO is administered <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                                    </content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the patient should seek medical attention and the healthcare professional should institute appropriate measures, if needed <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="xmChange">For detailed instructions on the preparation and administration of VYVGART HYTRULO prefilled syringe see <content styleCode="italics">
                                       <linkHtml href="#IFU">INSTRUCTIONS FOR USE</linkHtml>.</content>
                                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ad51516e-591b-4c16-924b-98c77d560ec8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Single-Dose Vial</content>
                              </paragraph>
                              <paragraph>Use aseptic technique when preparing and administering VYVGART HYTRULO vial. Do not shake the vial. Each vial is for one-time use only. Avoid exposure to direct sunlight. </paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                           <component>
                              <section>
                                 <id root="5b0d1d98-7d4d-4c98-b55d-662f456b45d7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Preparation</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="disc">
                                       <item>Take the VYVGART HYTRULO vial out of the refrigerator at least 15 minutes before injecting to allow it to reach room temperature <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>].</content> Do not use external heat sources.</item>
                                       <item>Check that the VYVGART HYTRULO solution is yellowish, clear to opalescent. </item>
                                       <item>Parenteral medicine products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. Do not use if opaque particles or other foreign particles are present.</item>
                                       <item>Withdraw the entire content of VYVGART HYTRULO from the vial using a polypropylene syringe and an 18G stainless steel transfer needle.</item>
                                       <item>Remove large air bubbles, if present. </item>
                                       <item>Each vial contains overfill to compensate for liquid loss during preparation and to compensate for the priming volume of the winged infusion set.</item>
                                       <item>VYVGART HYTRULO vial does not contain preservatives. Administer immediately after preparation.</item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250416"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1400a8d5-d862-447d-af29-b5aa59edaa1e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Administration</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="disc">
                                       <item>To administer VYVGART HYTRULO vial use a winged infusion set made of polyvinyl chloride (PVC), 25G, 12 inches tubing, maximum priming volume of 0.4 mL.</item>
                                       <item>Remove the transfer needle from the syringe and connect the syringe to the winged infusion set. </item>
                                       <item>Prior to administration, fill the tubing of the winged infusion set by gently pressing the syringe plunger until the plunger is at 5.6 mL.  There should be solution at the end of the winged infusion set needle.</item>
                                       <item>Choose an injection site on the abdomen (at least 2 to 3 inches away from the navel). 											<list listType="unordered" styleCode="circle">
                                             <item>Do not inject on areas where the skin is red, bruised, tender, hard, or into areas where there are moles or scars.</item>
                                             <item>Rotate injection sites for subsequent administrations.</item>
                                          </list>
                                       </item>
                                       <item>Inject VYVGART HYTRULO vial subcutaneously into a pinched skin area at an angle of about 45 degrees over 30 to 90 seconds.</item>
                                       <item>Localized injection site reactions may occur after VYVGART HYTRULO is administered. <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. </item>
                                       <item>Discard any unused portions of medicine remaining in the vial, the syringe and the winged infusion set.</item>
                                       <item>Healthcare professionals should monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                                       </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250416"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="9d26b869-ebea-40d1-bf60-91074ee3295d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase per 5 mL (200 mg/2,000 units per mL) as yellowish, clear to opalescent solution, in a single-dose prefilled syringe.</paragraph>
                  <paragraph>Injection: 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per 5.6 mL (180 mg/2,000 units per mL) as yellowish, clear to opalescent solution, in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase per 5 mL (200 mg/2,000 units per mL) in a single-dose prefilled syringe. (<linkHtml href="#S3">3</linkHtml>)  </paragraph>
                        <paragraph>Injection: 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per  5.6 mL (180 mg/2,000 units per mL) in a single-dose vial. (<linkHtml href="#S3">3</linkHtml>)  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4de7d919-0d59-47fc-8660-b5f5a2a9d6a6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO.  Reactions have included anaphylaxis and hypotension leading to syncope <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="b1e40dd2-2ddd-49c7-b772-76b78889983e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Infections: Delay administration of VYVGART HYTRULO to patients with an active infection. Monitor for signs and symptoms of infection in patients treated with VYVGART HYTRULO. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Hypersensitivity Reactions: Anaphylaxis, hypotension leading to syncope,  angioedema, dyspnea, rash, and urticaria have occurred in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab product. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Infusion/injection-Related Reactions: If a severe infusion/injection-related reaction occurs, initiate appropriate therapy; consider the risks and benefits of readministering.  If a mild to moderate infusion/injection-related reaction occurs, may rechallenge with close clinical observation, slower infusion/injection rates, and pre-medications. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="fbfe537f-d8b8-4929-ad64-f2beda9048bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Infections </title>
                     <text>
                        <paragraph>VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients compared to 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients compared to 29% of placebo-treated patients) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. A higher frequency of patients who received efgartigimod alfa-fcab compared to placebo were observed to have below normal levels for white blood cell counts (12% versus 5%, respectively), lymphocyte counts (28% versus 19%, respectively), and neutrophil counts (13% versus 6%, respectively).  The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection is resolved. During treatment with VYVGART HYTRULO, monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="fc4ec2ac-ba93-43c9-8c1d-37e1953581a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immunization</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in IgG levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="299b1006-0357-40a0-b4fb-349d34068cba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within one hour to three weeks of administration.</paragraph>
                        <paragraph>Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab.  Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation.</paragraph>
                        <paragraph>Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention. VYVGART HYTRULO is contraindicated in patients with a history of serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="268e856f-4bd4-4d8f-932f-051c47ee1d17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Infusion/Injection-Related Reactions</title>
                     <text>
                        <paragraph>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy.  Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="46570cc2-e7d0-46eb-b5a2-6b99f3227b0d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Infections <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Infusion/Injection-Related Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â¥ 10%) in patients with gMG treated with efgartigimod alfa-fcab were respiratory tract infections, headache, and urinary tract infection. </paragraph>
                        <paragraph>Injection site reactions were common (â¥ 15%) in patients with gMG and CIDP who were treated with VYVGART HYTRULO  (<linkHtml href="#S6.1">6.1</linkHtml>) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="221b15d1-905b-4463-8019-90c2aa8cb3a1"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1  Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="1ec8e594-7cbe-47b4-946d-71ab39b911f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Experience in Patients with gMG </content>
                              </paragraph>
                              <paragraph>The safety of efgartigimod alfa in patients with gMG was established in a double blinded placebo-controlled study with efgartigimod alfa-fcab administered intravenously (Study 1) and its open-label extension, and in an active-controlled study of VYVGART HYTRULO administered subcutaneously (Study 2) and its open-label extension <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="0b9fc358-4b85-4f42-a634-03374ff11fa6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Adverse Reactions with Efgartigimod Alfa-fcab Intravenous in Patients with gMG</content>
                                    </paragraph>
                                    <paragraph>In clinical studies, the safety of efgartigimod alfa-fcab administered intravenously has been evaluated in 246 patients with gMG who received at least one dose of efgartigimod alfa-fcab, including 57 patients exposed to at least 7 treatment cycles and 8 patients exposed to at least 10 treatment cycles. </paragraph>
                                    <paragraph>In a placebo-controlled study (Study 1) in patients with gMG, 84 patients received efgartigimod alfa-fcab 10 mg/kg <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Of these 84 patients, approximately 75% were female, 82% were White, 11% were Asian, and 8% were of Hispanic or Latino ethnicity. The mean age at study entry was 46 years (range 19 to 78). </paragraph>
                                    <paragraph>The minimum time to initiate a subsequent cycle, specified by study protocol, was 50 days from the start of the previous treatment cycle. On average, efgartigimod alfa-fcab-treated patients received 2 cycles in Study 1. The mean and median times to the second treatment cycle were 94 days and 72 days from the initial infusion of the first treatment cycle, respectively, for efgartigimod alfa-fcab-treated patients. </paragraph>
                                    <paragraph>Adverse reactions reported in at least 5% of patients treated with efgartigimod alfa-fcab and more frequently than placebo are summarized in Table 1. The most common adverse reactions (reported in at least 10% of efgartigimod alfa-fcab-treated patients) were respiratory tract infection, headache, and urinary tract infection.</paragraph>
                                    <table width="75%">
                                       <caption>Table 1: Adverse Reactions in at least 5% of Patients with gMG Treated with Efgartigimod Alfa-fcab Intravenously (EFG IV) and More Frequently than in Placebo-Treated Patients in Study 1 (Safety Population)</caption>
                                       <col width="55%" align="left" valign="top"/>
                                       <col width="25%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Adverse reaction</th>
                                             <th styleCode="Rrule">EFG IV<br/>(N=84)<br/>%</th>
                                             <th styleCode="Rrule">Placebo<br/>(N=83)<br/>%</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Respiratory tract infection 											</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">29</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Headache<footnote>
                                                   <content styleCode="italics">Headache includes migraine and procedural headache.</content>
                                                </footnote>
                                             </td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">29</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Paraesthesia<footnote>
                                                   <content styleCode="italics">Paresthesia includes oral hypoesthesia, hypoesthesia, and hyperesthesia.</content>
                                                </footnote>
                                             </td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Myalgia</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="00d7cbc3-4428-49e3-aab8-26be6f4f3daa"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Adverse Reactions with VYVGART HYTRULO in Patients with gMG</content>
                                    </paragraph>
                                    <paragraph>In an active-controlled study in patients with gMG (Study 2), 110 patients were randomized and received one cycle of once weekly administrations for 4 weeks (4 administrations total), of either VYVGART HYTRULO subcutaneously (n=55) or efgartigimod alfa-fcab intravenously (n=55) at recommended doses <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>. The open-label extension of Study 2 included some patients who switched from efgartigimod alfa-fcab IV to VYVGART HYTRULO. </paragraph>
                                    <paragraph>The most common adverse reactions (reported in at least 10% of VYVGART HYTRULO-treated patients) were injection site reactions and headache.</paragraph>
                                    <paragraph>In Study 2, injection site reactions occurred in 38% of patients receiving VYVGART HYTRULO. These were injection site rash, erythema, pruritus, bruising, pain, and urticaria.</paragraph>
                                    <paragraph>In Study 2 and its open-label extension (n = 168), all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.</paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="791f811f-22de-4270-982d-93a0df49e350"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Experience in Patients with CIDP </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="21062cb1-9949-46f9-8c78-2d5baf10979d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Adverse Reactions with VYVGART HYTRULO in Patients with CIDP</content>
                                    </paragraph>
                                    <paragraph>In a placebo-controlled study in patients with CIDP (Study 3, stage B), 221 patients were randomized to receive once-weekly administration of either VYVGART HYTRULO 1,008 mg /11, 200 units subcutaneously (n=111) or placebo (n=110) <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content> The mean duration of treatment with VYVGART HYTRULO in stage B was 25 weeks. The overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously.</paragraph>
                                    <paragraph>In Study 3, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.</paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="1e8a1f1a-40ac-4789-af18-2e7484bbcea4"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of efgartigimod alfa products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Immune System Disorders: Hypersensitivity reactions including anaphylaxis and hypotension, and infusion/injection-related reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3"> 5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="c3145928-083f-401c-bf0e-dfaea5cf6e1f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS </title>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. When concomitant long-term use of such medications is essential for patient care, consider discontinuing VYVGART HYTRULO and using alternative therapies. (<linkHtml href="#S7">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="c69336d6-6dec-4389-9596-995c6f696087"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of VYVGART HYTRULO on Other Drugs</title>
                     <text>
                        <paragraph>Concomitant use of VYVGART HYTRULO with medications that bind to the human neonatal Fc receptor (FcRn) (e.g., immunoglobulin products, monoclonal antibodies, or antibody derivates containing the human Fc domain of the IgG subclass) may lower systemic exposures and reduce effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. When concomitant long-term use of such medications is essential for patient care, consider discontinuing VYVGART HYTRULO and using alternative therapies.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="e9fe644f-948b-494e-b888-08e307139e60"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250416"/>
               <component>
                  <section ID="S8.1">
                     <id root="abd65cdc-1586-4165-9876-c068f55b8ed5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="aec66b9f-b8be-4ccf-a80a-950aa17ea581"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VYVGART HYTRULO during pregnancy. Healthcare providers and patients may call 1-855-272-6524 or go to https://www.Vyvgartpregnancy.com to enroll in or to obtain information about the registry.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="49bae27e-5655-4c64-8ace-fc167fbda108"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on the use of VYVGART HYTRULO or efgartigimod alfa containing products during pregnancy. There was no evidence of adverse developmental outcomes following the intravenous administration of efgartigimod alfa at up to 100 mg/kg/day in rats and rabbits (see <linkHtml href="#data">Data</linkHtml>). </paragraph>
                              <paragraph>The background rate of major birth defects and miscarriage in the indicated population is unknown. In the U.S. general population, the estimated background rate of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="da6a1cae-dda6-44a4-aa1b-da21b04958cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="8f4b1150-2a94-4cbc-9e49-88197ec0b67f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Therefore, efgartigimod alfa may be transmitted from the mother to the developing fetus.</paragraph>
                                    <paragraph>As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="56e99705-0b39-40d1-975d-3e8c122e6157"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="642d175e-5155-4ab7-a175-084ee6e226ae"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>VYVGART HYTRULO for subcutaneous injection contains efgartigimod alfa and hyaluronidase <content styleCode="italics">[see <linkHtml href="#S11">Description (11)</linkHtml>]</content>.</paragraph>
                                    <paragraph>Efgartigimod alfa:</paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <caption>-</caption>	Intravenous administration of efgartigimod alfa (0, 30, or 100 mg/kg/day) to pregnant rats and rabbits throughout organogenesis resulted in no adverse effects on embryofetal development in either species. Maternal efgartigimod alfa exposures at the highest no-effect doses were approximately 8 and 62 times, respectively, that in humans at the recommended human dose (RHD) of 1008 mg. </item>
                                       <item>
                                          <caption>-</caption>	Intravenous administration of efgartigimod alfa (0, 30, or 100 mg/kg/day) to rats throughout gestation and lactation resulted in no adverse effects on pre- or postnatal development. Maternal exposures at the highest no-effect dose were approximately 13 times that in humans at the RHD.  </item>
                                    </list>
                                    <paragraph>Hyaluronidase:</paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <caption>-</caption>	In a study in which hyaluronidase (human recombinant) was administered by subcutaneous injection to pregnant mice throughout organogenesis, increased embryofetal mortality and decreased fetal body weights were observed at the highest doses tested. The no-effect dose for adverse effects on embryofetal development in the mouse was approximately 1800 times the dose of hyaluronidase at the recommended human dose (RHD) of VYVGART HYTRULO (1,008 mg efgartigimod alfa and 11,200 U hyaluronidase), on a U/kg basis.</item>
                                       <item>
                                          <caption>-</caption>	There were no adverse effects on pre- and postnatal development following subcutaneous administration of hyaluronidase (human recombinant) to mice throughout gestation and lactation at doses up to 5,000 times the dose of hyaluronidase at the RHD of VYVGART HYTRULO, on a U/kg basis.</item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="627d726e-e185-4b82-891e-320dca004ef0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2  Lactation </title>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="66291b69-1e92-4805-b167-b6210d9b7858"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk.</paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="a685e8c4-9725-48f0-9457-5081cb90f494"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="61bc6e77-8432-447b-b1ce-f565990ee5aa"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use </title>
                     <text>
                        <paragraph>Clinical studies of VYVGART HYTRULO did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6b264c9e-f1a2-4186-a950-14c53c7531e4"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment of VYVGART HYTRULO is needed for patients with mild renal impairment. There are insufficient data to evaluate the impact of moderate renal impairment (eGFR 30-59 mL/min/1.73 m<sup>2</sup>) and severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) on pharmacokinetic parameters of VYVGART HYTRULO <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="50bf8553-8489-4027-9fdb-1009cb50e2d5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION </title>
               <text>
                  <paragraph>VYVGART HYTRULO is a fixed-combination drug product containing efgartigimod alfa and hyaluronidase (human recombinant).</paragraph>
                  <paragraph>Efgartigimod alfa, a neonatal Fc receptor blocker, is a human immunoglobulin G1 (IgG1) -derived Fc fragment (fragment, crystallized) of the za allotype, produced in Chinese hamster ovary (CHO) cells. The efgartigimod alfa Fc fragment is a homodimer consisting of two identical peptide chains each consisting of 227 amino acids linked together by two interchain disulfide bonds with affinity for FcRn. The molecular weight of efgartigimod alfa is approximately 54 kDa.</paragraph>
                  <paragraph>Hyaluronidase (human recombinant) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. Hyaluronidase (human recombinant) is a glycosylated single-chain protein produced by Chinese hamster ovary cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase (human recombinant) has a molecular weight of approximately 61 kDa.</paragraph>
                  <paragraph>VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection is a sterile, preservative free, yellowish, clear to opalescent solution supplied in a single-dose prefilled syringe or vial for subcutaneous injection.</paragraph>
                  <paragraph>Each 5 mL single-dose prefilled syringe contains 1,000 mg of efgartigimod alfa and 10,000 units of hyaluronidase (human recombinant). Each mL contains 200 mg of efgartigimod alfa, 2,000 units of hyaluronidase (human recombinant) and arginine hydrochloride (10.5 mg), histidine (1.4 mg), L-histidine hydrochloride monohydrate (2.2 mg), methionine (1.5 mg), polysorbate 80 (0.4 mg), sodium chloride (4.1 mg), sucrose (20.5 mg), and Water for Injection, USP, at a pH of 6.0.</paragraph>
                  <paragraph>Each 5.6 mL single-dose vial contains 1,008 mg of efgartigimod alfa and 11,200 units of hyaluronidase (human recombinant). Each mL contains 180 mg of efgartigimod alfa, 2,000 units of hyaluronidase (human recombinant) and histidine (1.4 mg), L-histidine hydrochloride monohydrate (2.2 mg), methionine (1.5 mg), polysorbate 20 (0.4 mg), sodium chloride (5.8 mg), sucrose (20.5 mg), and Water for Injection, USP, at a pH of 6.0.</paragraph>
               </text>
               <effectiveTime value="20250416"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="be848447-5d03-413b-a475-36d15195c714"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250414"/>
               <component>
                  <section ID="S12.1">
                     <id root="f1bbdaf7-c1af-4710-b188-9983393b0591"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	 Mechanism of Action</title>
                     <text>
                        <paragraph>VYVGART HYTRULO is a coformulation of efgartigimod alfa and hyaluronidase.</paragraph>
                        <paragraph>Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.</paragraph>
                        <paragraph>Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. This effect is transient, and permeability of the subcutaneous tissue is restored within 24 to 48 hours.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="d566d715-1097-4474-813b-129d7456ab07"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics </title>
                     <text>
                        <paragraph>In Study 1 <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>],</content> the pharmacological effect of efgartigimod alfa-fcab was assessed by measuring the decrease in serum IgG levels and AChR autoantibody levels. In patients testing positive for AChR antibodies and who were treated with efgartigimod alfa-fcab intravenous, there was a reduction in total IgG levels relative to baseline. Decrease in AChR autoantibody levels followed a similar pattern. A decrease in AChR-Ab was associated with a clinical response in AChR-Ab positive patients, as measured by the change from baseline in MG-ADL total score.</paragraph>
                        <paragraph>In Study 2, the pharmacological effect of VYVGART HYTRULO administered subcutaneously (SC) at 1,008 mg / 11,200 Units was compared to efgartigimod alfa-fcab administered intravenously at 10 mg/kg (EFG IV) in gMG patients. The maximum mean reduction in AChR-Ab level was observed at week 4, with a mean reduction of 62.2% and 59.7% in the VYVGART HYTRULO SC and efgartigimod alfa-fcab IV arm, respectively. The decrease in total IgG levels followed a similar pattern. The 90% confidence intervals for the geometric mean ratios of AChR-Ab reduction at day 29 and AUEC<sub>0-4w</sub> (area under the effect-time curve from time 0 to 4 weeks post dose) were within the range of 80% to 125%, indicating no clinically significant difference between the two formulations. </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="6fce99e9-e62f-4e50-abe2-9bf82ccc076e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph>Efgartigimod alfa exposures were approximately dose-proportional up to the highest subcutaneously tested dose of VYVGART HYTRULO (1750 mg, 1.75 times the recommended dosage).</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                     <component>
                        <section>
                           <id root="368f701f-57f5-4e0f-b830-2450feecd4ce"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The rate and extent of absorption from a single-dose prefilled syringe and single-dose vial are similar.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="304c7957-cd93-42b2-8e7b-2fdd641734c5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The volume of distribution is 15 to 20L.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7f19f98a-acac-4719-9dcf-6a65ea5dbf48"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism and Elimination</content>
                              </paragraph>
                              <paragraph>Efgartigimod alfa and hyaluronidase are expected to be degraded by proteolytic enzymes into small peptides and amino acids.</paragraph>
                              <paragraph>The terminal half-life is 80 to 120 hours (3 to 5 days).</paragraph>
                              <paragraph>After a single intravenous dose of 10 mg/kg efgartigimod alfa-fcab in healthy subjects, less than 0.1% of the administered dose was recovered in urine. </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="deeaf4b5-cab6-4be9-b7eb-1a01680f8c3a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="b28b6c25-f882-4782-ba2e-276109e630d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age, Sex and Race</content>
                                    </paragraph>
                                    <paragraph>A population pharmacokinetics analysis assessing the effects of age, body weight, sex, and race did not suggest any clinically significant impact of these covariates on efgartigimod alfa exposures.</paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="38b725be-3262-4cbf-995f-a953f2d28524"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Body Weight</content>
                                    </paragraph>
                                    <paragraph>A population pharmacokinetics analysis suggests that the influence of body weight on efgartigimod alfa exposure after administration of VYVGART HYTRULO SC 1008 mg was limited and not clinically relevant.</paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2334cd3c-becc-414b-821e-82d1631215f9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>No dedicated pharmacokinetic study has been performed in patients with renal impairment. </paragraph>
                                    <paragraph>Population PK analyses of data from the VYVGART HYTRULO clinical studies indicated that patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m<sup>2</sup>) had 11 to 20% increase in exposure relative to the exposure in patients with normal renal function <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="b32a2c78-556c-42ab-926c-0cb0e41544b7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>No dedicated pharmacokinetic study has been performed in patients with hepatic impairment. Hepatic impairment is not expected to affect the pharmacokinetics of efgartigimod alfa.  </paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ed462f45-cb36-428f-a4c4-3f7604c102a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>Clinical drug interactions studies have not been performed with efgartigimod alfa.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                           <component>
                              <section>
                                 <id root="11502304-5b12-4254-ab38-085ff0cd9555"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">P450 Enzymes</content>
                                    </paragraph>
                                    <paragraph>Efgartigimod alfa is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely. </paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="460cc2fb-884b-4255-b12f-973880720a6f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Drug Interactions with Other Drugs or Biological Products</content>
                                    </paragraph>
                                    <paragraph>Efgartigimod alfa may decrease concentrations of compounds that bind to the human FcRn <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250414"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="eb692e4f-c054-4f9f-9df4-b41f5b373d28"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6  Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of VYVGART HYTRULO or of other efgartigimod products.</paragraph>
                        <paragraph>In Study 2, in up to 10 weeks following the initiation of a treatment period with 4 weekly administrations, the incidence of anti-efgartigimod alfa antibodies was 35% (19/55) following treatment with VYVGART HYTRULO and 20% (11/55) in patients receiving intravenous efgartigimod alfa-fcab. For both IV and SC arms, neutralizing anti-efgartigimod alfa antibodies were detected in 4% (2/55) of patients.</paragraph>
                        <paragraph>In Study 3, in up to 12 weeks of treatment in stage A and 48 weeks in stage B, the incidence of anti-efgartigimod alfa antibodies was 6% (20/317) in stage A and 2% (2/111) in stage B, following treatment with VYVGART HYTRULO. Neutralizing anti-efgartigimod alfa antibodies were detected in 0.3% (1/317) of patients in stage A and in no patient in stage B.</paragraph>
                        <paragraph>Some neutralizing antibodies may not be detected by the assay. The available data are too limited to make definitive conclusions regarding immunogenicity and the effect on pharmacokinetics, safety, or efficacy of VYVGART HYTRULO.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="a5ad295a-4140-4fe5-b21f-a386d15e3eff"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250416"/>
               <component>
                  <section ID="S13.1">
                     <id root="71f17f65-f5f7-4985-ba92-3652fe0abd67"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>VYVGART HYTRULO for subcutaneous injection contains efgartigimod alfa and hyaluronidase <content styleCode="italics">[see <linkHtml href="#S11">Description (11)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="9e12832b-69fb-4316-836c-9c221a50c436"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis and Mutagenesis</content>
                              </paragraph>
                              <paragraph>No studies have been conducted to assess the carcinogenic potential of efgartigimod alfa.</paragraph>
                              <paragraph>No studies have been conducted to assess the genotoxic potential of efgartigimod alfa.</paragraph>
                              <paragraph>No carcinogenicity or genotoxicity studies were conducted for human recombinant hyaluronidase.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="df1f5fb5-4921-4897-9ad8-a615ba5686ec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Intravenous administration of efgartigimod alfa (0, 30, or 100 mg/kg/day) to male and female rats prior to and during mating and continuing in females through gestation day 7 resulted in no adverse effects on fertility. Efgartigimod alfa exposures at the highest no-effect dose were approximately 12 times that in humans at the recommended human dose of 1008 mg. There were no effects on reproductive tissues in monkeys following subcutaneous administration of hyaluronidase (human recombinant) doses up to approximately 1,200 times the dose of hyaluronidase at the recommended human dose (RHD) of VYVGART HYTRULO (1,008 mg efgartigimod alfa and 11,200 U hyaluronidase) on a U/kg basis for 39 weeks. No systemic exposure to hyaluronidase was observed at doses up to approximately 120 times the dose of hyaluronidase at the RHD of VYVGART HYTRULO, on a U/kg basis.</paragraph>
                           </text>
                           <effectiveTime value="20250414"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="fdb8c979-ef40-466f-b2e0-f7a490dfe21a"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <effectiveTime value="20250416"/>
               <component>
                  <section ID="S14.1">
                     <id root="832b11fd-5414-46b0-bcba-31a941462f26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Generalized Myasthenia Gravis </title>
                     <text>
                        <paragraph>Study 1 (described below) which established the effectiveness of efgartigimod alfa-fcab for the treatment of generalized myasthenia gravis (gMG) in adults who are AChR antibody positive was conducted with efgartigimod alfa-fcab intravenous formulation. In Study 2, VYVGART HYTRULO demonstrated a comparable pharmacodynamic effect on AChR antibody reduction as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of VYVGART HYTRULO <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="aff5ff55-2ba1-4d77-b7f7-c9dc73d0c7ea"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study 1 (Efgartigimod Alfa-fcab Intravenous)</content>
                              </paragraph>
                              <paragraph>The efficacy of efgartigimod alfa-fcab intravenous (EFG IV) for the treatment of generalized myasthenia gravis (gMG) in adults who are AChR antibody positive was established in a 26-week, multicenter, randomized, double-blind, placebo-controlled trial (Study 1; NCT03669588).</paragraph>
                              <paragraph>Study 1 enrolled patients who met the following criteria at screening: </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>-</caption>	Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV</item>
                                 <item>
                                    <caption>-</caption>	MG-Activities of Daily Living (MG-ADL) total score of â¥ 5</item>
                                 <item>
                                    <caption>-</caption>	On stable dose of MG therapy prior to screening, that included acetylcholinesterase (AChE) inhibitors, steroids, or non-steroidal immunosuppressive therapies (NSISTs), either in combination or alone </item>
                                 <item>
                                    <caption>-</caption>	IgG levels of at least 6 g/L</item>
                              </list>
                              <paragraph>A total of 167 patients were enrolled in Study 1 and were randomized to receive either EFG IV 10mg/kg (1200 mg for those weighing 120 kg or more) (n=84) or placebo (n=83). Baseline characteristics were similar between treatment groups. Patients had a median age of 46 years at screening (range: 19 to 81 years) and a median time since diagnosis of 7 years. Seventy-one percent were female, and 84% were White. Median MG-ADL total score was 9, and median Quantitative Myasthenia Gravis (QMG) total score was 16. The majority of patients (n=65 for EFG IV; n=64 for placebo) were positive for AChR antibodies.</paragraph>
                              <paragraph>At baseline, over 80% of patients in each group received AChE inhibitors, over 70% in each treatment group received steroids, and approximately 60% in each treatment group received NSISTs, at stable doses. </paragraph>
                              <paragraph>Patients were treated with 10 mg/kg EFG IV administered as an intravenous infusion over one hour once weekly for 4 weeks.  In patients weighing 120 kg or more, EFG IV was administered as 1200 mg per infusion. Subsequent treatment cycles were administered based on clinical evaluation, but no sooner than 50 days from the start of the previous treatment cycle.</paragraph>
                              <paragraph>The efficacy of EFG IV was measured using the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG. Each item is assessed on a 4-point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. A total score ranges from 0 to 24, with the higher scores indicating more impairment. In this study, an MG-ADL responder was defined as a patient with a 2-point or greater reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after the last infusion of the cycle. </paragraph>
                              <paragraph>The primary efficacy endpoint was the comparison of the percentage of MG-ADL responders during the first treatment cycle between treatment groups in the AChR-Ab positive population. A statistically significant difference favoring EFG IV was observed in the MG-ADL responder rate during the first treatment cycle [67.7% in the EFG IV-treated group vs 29.7% in the placebo-treated group (p &lt;0.0001)].</paragraph>
                              <paragraph>The efficacy of EFG IV was also measured using the Quantitative Myasthenia Gravis (QMG) total score which is a 13-item categorical grading system that assesses muscle weakness. Each item is assessed on a 4-point scale where a score of 0 represents no weakness and a score of 3 represents severe weakness. A total possible score ranges from 0 to 39, where higher scores indicate more severe impairment. In this study, a QMG responder was defined as a patient who had a 3-point or greater reduction in the total QMG score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after last infusion of the cycle.</paragraph>
                              <paragraph>The secondary endpoint was the comparison of the percentage of QMG responders during the first treatment cycle between both treatment groups in the AChR-Ab positive patients. A statistically significant difference favoring EFG IV was observed in the QMG responder rate during the first treatment cycle [63.1% in the EFG IV-treated group vs 14.1% in the placebo-treated group (p &lt;0.0001)].</paragraph>
                              <paragraph>The results are presented in Table 2.</paragraph>
                              <table width="80%">
                                 <caption>Table 2: MG-ADL and QMG Responders During Cycle 1 in AChR-Ab Positive Patients (mITT Analysis Set)</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="18%" align="center" valign="top"/>
                                 <col width="18%" align="center" valign="top"/>
                                 <col width="18%" align="center" valign="top"/>
                                 <col width="26%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">EFG IV<br/>n=65<br/>%</th>
                                       <th styleCode="Rrule">Placebo<br/>n=64<br/>%</th>
                                       <th styleCode="Rrule">P-value</th>
                                       <th styleCode="Rrule">Odds Ratio (95% CI)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="5">EFG IV= Efgartigimod alfa-fcab intravenous; MG-ADL=Myasthenia Gravis Activities of Daily Living; QMG =Quantitative Myasthenia Gravis; mITT=modified intent-to-treat; n=number of patients for whom the observation was reported; CI = confidence interval;<br/>Logistic regression stratified for AChR-Ab status (if applicable), Japanese/Non-Japanese and standard of care, with baseline MG-ADL as covariate / QMG as covariates<br/>Two-sided exact p-value</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">MG-ADL Responders</td>
                                       <td styleCode="Rrule">67.7</td>
                                       <td styleCode="Rrule">29.7</td>
                                       <td styleCode="Rrule">&lt; 0.0001</td>
                                       <td styleCode="Rrule">4.951 (2.213, 11.528)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="middle">QMG Responders</td>
                                       <td styleCode="Rrule">63.1</td>
                                       <td styleCode="Rrule">14.1</td>
                                       <td styleCode="Rrule">&lt; 0.0001</td>
                                       <td styleCode="Rrule">10.842 (4.179, 31.200)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Figure 1 shows the mean change from baseline on the MG-ADL during cycle 1.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Mean Change in Total MG-ADL From Cycle 1 Baseline Over Time in AChR-Ab Positive Patients (mITT Analysis Set)</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM1"/>
                              <paragraph>Figure 2 shows the distribution of response on the MG-ADL and QMG during cycle 1, four weeks after the first infusion with EFG IV.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 2: Percentage of Patients with MG-ADL and QMG Total Score Change 4 Weeks Post Initial Infusion of the First Cycle in AChR-Ab Positive Patients</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM2"/>
                           </text>
                           <effectiveTime value="20250416"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="vyvgart-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 2</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="vyvgart-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="bb1d24c1-15e4-4683-8698-096af6598faa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Chronic Inflammatory Demyelinating Polyneuropathy </title>
                     <text>
                        <paragraph>The efficacy of VYVGART HYTRULO for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) was established in a two stage, multicenter study (Study 3; NCT04281472). Study 3 included an open-label period to identify VYVGART HYTRULO responders (stage A) who then entered a randomized, double-blind, placebo-controlled, withdrawal period (stage B).</paragraph>
                        <paragraph>Study 3 enrolled male and female patients age 18 years and older, who at the time of screening, had a documented diagnosis of definite or probable CIDP using the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS; 2010) criteria for progressing or relapsing forms.</paragraph>
                        <paragraph>The Inflammatory Neuropathy Cause and Treatment disability score (INCAT) is a scale used to assess the impact of CIDP on daily upper and lower limb function, and is composed of the arm score and leg score (0 to 5 points for each). A total score on the INCAT ranges from 0 to 10 points with a higher number representing more disability.  The adjusted INCAT (aINCAT) disability score, identical to the INCAT disability score but with changes in the upper limb function from 0 (normal) to 1 (minor symptoms) excluded, was used to assess efficacy for VYVGART HYTRULO for the treatment of CIDP.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                     <component>
                        <section>
                           <id root="9f3aab7b-0f3d-4605-a3d6-4888d87f9748"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Stage A</content>
                              </paragraph>
                              <paragraph>In stage A, a total of 322 patients received up to 12 once weekly subcutaneous injections of VYVGART HYTRULO 1008 mg / 11,200 units until evidence of improvement occurred at two consecutive study visits. Improvement was defined as aINCAT improvement â¥1 point, I-RODS improvement â¥4 points, or mean grip strength improvement â¥ 8 kPa. Stage A included 228 patients currently receiving standard-of-care therapy and 94 patients who had either not received prior treatment for CIDP or were not treated with standard-of-care therapy for at least 6 months before study entry. Sixty-nine percent of patients (n=221) who had documented improvement at two consecutive visits during Stage A then entered Stage B.</paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3a5583f5-6448-4ba5-95d4-2cd13e1f8ec9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Stage B</content>
                              </paragraph>
                              <paragraph>In stage B, a total of 221 patients were randomized to receive once weekly subcutaneous injections of VYVGART HYTRULO 1008 mg / 11,200 units (n=111) or placebo (n=110).</paragraph>
                              <paragraph>Baseline characteristics of patients in stage B were similar between treatment groups. Patients had a median age of 55 years (range: 20 to 82 years), a median time since CIDP diagnosis of 2.2 years, and median INCAT score of 3.0. Sixty-four percent were male and 65% were White, 30% Asian, and 1% African American.</paragraph>
                              <paragraph>Stage B included 146 patients currently receiving standard-of-care therapy and 75 patients who had either not received prior treatment for CIDP or were not treated with standard-of-care therapy for at least 6 months before study entry.</paragraph>
                              <paragraph> The primary endpoint was the time to clinical deterioration defined as a 1-point increase in aINCAT at two consecutive visits or a &gt;1-point increase in aINCAT at one visit.  Patients who had clinical deterioration or completed week 48 in Stage B without clinical deterioration were withdrawn from the placebo-controlled portion of the study. The study stopped when 88 events of clinical deterioration occurred for the primary endpoint analysis.</paragraph>
                              <paragraph>Patients who received VYVGART HYTRULO experienced a longer time to clinical deterioration (i.e., increase of â¥1 point in aINCAT score) compared to patients who received placebo, which was statistically significant, as demonstrated by a hazard ratio of 0.394 [95% CI (0.253; 0.614)  p&lt;0.0001]. The results are presented in Table 3 and Figure 3.</paragraph>
                              <table width="80%">
                                 <caption>Table 3: Time to First Increase of â¥1 Point in aINCAT Score In Patients With CIDP In Study 3 Stage B</caption>
                                 <col width="60%" align="left" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="3"/>
                                       <th styleCode="Rrule" colspan="2">Stage B</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">VYVGART HYTRULO</th>
                                       <th styleCode="Rrule" valign="top">Placebo</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom" align="center">(N=111)</th>
                                       <th styleCode="Rrule" valign="bottom">(N=110)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="3">N=number of patients in the analysis set; %: percentage; aINCAT: adjusted Inflammatory Neuropathy Cause and Treatment </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Time to 1<sup>st</sup> aINCAT increase (clinical deterioration) in days</td>
                                       <td styleCode="Rrule" colspan="2"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Â Â Hazard ratio (95% CI)</td>
                                       <td styleCode="Rrule" valign="top" colspan="2">0.394 (0.253; 0.614)<br/>p-value &lt;0.0001</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 3: Time To The First aINCAT Increase (Kaplan-Meier Curve) In Patients With CIDP In Study 3 Stage B</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM3"/>
                              <paragraph>Note: The time to clinical deterioration is defined as the time in days from the first VYVGART HYTRULO or placebo administration in Stage B to the first occurrence of either: an increase in aINCAT score of 1 point compared with Stage B baseline if confirmed at the next visit or an increase in aINCAT score of &gt;1 point compared with Stage B baseline.</paragraph>
                           </text>
                           <effectiveTime value="20250416"/>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 3</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="vyvgart-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="b18ed669-5086-40f7-93d1-7990e6f9761c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection is a preservative free, sterile, yellowish, clear to opalescent solution supplied as a single-dose prefilled syringe or vial.  </paragraph>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <section>
                     <id root="75833327-b431-4d4c-8b95-e26c5a16f61e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Single-Dose Prefilled Syringe</content>
                        </paragraph>
                        <paragraph>Each single-dose prefilled syringe contains 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase per 5 mL (200 mg/2,000 units per mL). It is available in cartons of one or four single-dose prefilled syringes (NDC 73475-1221-1 or NDC 73475-1221-4). The safety needle that is 25G, 5/8 inches length, and thin wall type is not included in the carton.</paragraph>
                        <paragraph>Store VYVGART HYTRULO prefilled syringe refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original carton to protect from light until time of use. Do not freeze. Do not shake.</paragraph>
                        <paragraph>If needed, prefilled syringes may be stored at room temperature at up to 30Â°C (86Â°F) in the original carton for a single period of up to 30 days after removing from refrigerator or until expiration date on the carton, whichever occurs first. Record the date removed from the refrigerator on the carton.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="189342df-e468-4daa-9601-c42b28767a14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Single-Dose Vial</content>
                        </paragraph>
                        <paragraph>Each single-dose vial contains 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per 5.6 mL (180 mg/2,000 units per mL). It is available in carton of one single-dose vial (NDC 73475-3102-3).</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9b61d59f-a4c8-45f8-a5f1-6cd460a3a68f"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store VYVGART HYTRULO vials refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original carton to protect from light until time of use. Do not freeze. Do not shake. </paragraph>
                        <paragraph>If needed, unopened vials may be stored in the original carton for up to 3 days at room temperature at 20Â°C to 25Â°C (68Â°F to 77Â°F) for a single period before administration or returned to refrigeration.  Do not store the vial at room temperature more than one time. Record the date removed from and the date returned to the refrigerator on the carton.</paragraph>
                     </text>
                     <effectiveTime value="20250416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="704d7ef4-e4bb-49e0-b5c7-49b7dd811488"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient and/or caregiver to read FDA-approved patient labeling (Patient Information and Instructions for Use). </paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <component>
                  <section>
                     <id root="a2ad3921-3149-4ad4-b790-438e86267baa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infections</content>
                        </paragraph>
                        <paragraph>Instruct patients to communicate any history of infections to the healthcare provider and to contact their healthcare provider if they develop any symptoms of an infection. Advise patients to complete age-appropriate vaccines according to immunization guidelines prior to initiation of a new treatment cycle with VYVGART HYTRULO. Administration of live vaccines is not recommended during treatment with VYVGART HYTRULO <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7aec8200-377f-4502-9acd-5b9e6dba3537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with efgartigimod alfa products. Inform patients about the signs and symptoms of these reactions, and advise patients to contact their healthcare provider immediately if these occur <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1b27ae58-a06c-47a0-99ae-86684858aea9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion/injection-Related Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients of the potential risk of infusion/injection-related reactions, which can include hypertension, chills, shivering, and chest, abdominal, and back pain <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ca4486cb-0b3f-4368-a8c4-7a0c549ac526"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Instruction on Injection Technique</content>
                        </paragraph>
                        <paragraph>If a patient or caregiver is to administer subcutaneous VYVGART HYTRULO prefilled syringe, instruct them in proper injection technique (e.g., site selection and duration of injection) <content styleCode="italics">[see <linkHtml href="#IFU">Instructions for Use</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bdefed2b-5d7f-4da3-83a5-169164e7da03"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VYVGART HYTRULO during pregnancy. Encourage participation and advise patients about how they may enroll in the registry <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8a1c12c4-db99-4751-bde4-ef254ff47db0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>argenx BV<br/>Industriepark 7<br/>9052 Zwijnaarde, Belgium<br/>U.S. License No. 2217</paragraph>
                  <paragraph>Halozyme, Inc.<br/>12390 El Camino Real<br/>San Diego, CA 92130<br/>U.S. License  No. 2187</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>argenx US, Inc.<br/>33 Arch Street<br/>Boston, MA 02110 </paragraph>
                  <paragraph>VYVGART HYTRULO is a registered trademark of argenx BV.<br/>Â© 2025 argenx BV</paragraph>
                  <paragraph>For patent information: www.argenx.com/patents</paragraph>
               </text>
               <effectiveTime value="20250416"/>
            </section>
         </component>
         <component>
            <section ID="PPI">
               <id root="66857476-822c-41d1-8ebd-deeddd640973"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="17%" align="left" valign="top"/>
                     <col width="17%" align="left" valign="top"/>
                     <col width="33%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" align="center" colspan="5">PATIENT INFORMATION<br/>VYVGART HYTRULO<sup>Â®</sup> [viv' gart hye troo' loe]<br/>(efgartigimod alfa and hyaluronidase-qvfc)<br/>injection, for subcutaneous use</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="left">Revised: 4/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What is VYVGART HYTRULO?</content>
                              <br/>VYVGART HYTRULO is a prescription medicine used to treat adults with: 									<list listType="unordered" styleCode="Disc">
                                 <item>generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.</item>
                                 <item>chronic inflammatory demyelinating polyneuropathy (CIDP).</item>
                              </list>It is not known if VYVGART HYTRULO is safe and effective in children. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Do not take VYVGART HYTRULO</content> if you: 									<list listType="unordered" styleCode="Disc">
                                 <item>are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. See the end of this leaflet for a complete list of ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have an infection or fever.</item>
                                 <item>have recently received or are scheduled to receive any vaccinations. </item>
                                 <item>have any history of allergic reactions.</item>
                                 <item>have kidney (renal) problems.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Pregnancy Exposure Registry</content>. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to https://www.Vyvgartpregnancy.com </item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk. </item>
                              </list>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">How should I take VYVGART HYTRULO?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take VYVGART HYTRULO exactly as your healthcare provider tells you to take it.  </item>
                                 <item>VYVGART HYTRULO is injected under your skin (subcutaneously) only. <content styleCode="bold">Do not</content> inject into a vein (intravenously). </item>
                                 <item>For gMG, VYVGART HYTRULO is injected 1 time weekly for 4 weeks (treatment cycle). Your healthcare provider will tell you when to administer your future treatment cycles. </item>
                                 <item>For CIDP, VYVGART HYTRULO is injected 1 time weekly.</item>
                                 <item>VYVGART HYTRULO comes in a single-dose prefilled syringe and single-dose vial.</item>
                                 <item>Only a healthcare provider should inject VYVGART HYTRULO using the single-dose vial.</item>
                                 <item>If you are prescribed the VYVGART HYTRULO prefilled syringe, you or your caregiver should receive training on the right way to prepare and inject VYVGART HYTRULO prefilled syringe.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> try to inject VYVGART HYTRULO prefilled syringe until you have been shown the right way by a healthcare provider. <content styleCode="bold">See the detailed <linkHtml href="#IFU">Instructions for Use</linkHtml> that comes with VYVGART HYTRULO prefilled syringe.</content>
                                 </item>
                                 <item>Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after administration. See "<content styleCode="bold">
                                       <linkHtml href="#effects">What are the possible side effects of VYVGART HYTRULO?</linkHtml>"</content>
                                 </item>
                                 <item>If you miss a dose of VYVGART HYTRULO, you may give the injection for up to 3 days after the missed dose. After that, continue with the normal time between doses (dosing schedule).</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold" ID="effects">What are the possible side effects of VYVGART HYTRULO?<br/>VYVGART HYTRULO can cause side effects which can be serious, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infection.</content> VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>fever</item>
                                 <item>chills</item>
                                 <item>frequent and painful urination</item>
                                 <item>cough</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>pain and blockage of nasal passages</item>
                                 <item>wheezing</item>
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>sore throat</item>
                                 <item>excess phlegm</item>
                                 <item>nasal discharge</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Allergic reactions (hypersensitivity reactions).</content> VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:  </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>rash</item>
                                 <item>swelling of the face, lips, throat, or tongue</item>
                                 <item>shortness of breath </item>
                                 <item>hives</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>trouble breathing</item>
                                 <item>low blood pressure</item>
                                 <item>fainting</item>
                              </list>
                           </td>
                           <td/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infusion or injection-related reactions.</content> VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>high blood pressure</item>
                                 <item>chills</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>shivering</item>
                                 <item>chest, stomach, or back pain </item>
                              </list>
                           </td>
                           <td/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">The most common side effects of VYVGART HYTRULO include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>respiratory tract infection</item>
                                 <item>injection site reactions</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>headache</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>urinary tract infection</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">How should I store VYVGART HYTRULO?</content>
                              <br/>
                              <content styleCode="underline">Refrigerated </content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store VYVGART HYTRULO in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C).</item>
                                 <item>Only warm VYVGART HYTRULO by letting it sit on a flat surface for at least 30 minutes for the prefilled syringe and 15 minutes for the vial. Do not warm VYVGART HYTRULO any other way (e.g., with an external heat source).</item>
                                 <item>Store VYVGART HYTRULO in the original carton to protect from light until you are ready to use it.</item>
                                 <item>Do not freeze VYVGART HYTRULO.</item>
                                 <item>Do not shake VYVGART HYTRULO.</item>
                                 <item>Do not use VYVGART HYTRULO past the expiration date.</item>
                                 <item>VYVGART HYTRULO is for one-time use only (single-dose). </item>
                                 <item>Remove from the refrigerator only the dose you are preparing to inject. Future doses should remain refrigerated until ready to use.</item>
                              </list>
                              <content styleCode="underline">Room temperature</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If needed, VYVGART HYTRULO may be stored at room temperature. Record the date you removed VYVGART HYTRULO from the refrigerator.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>Single-dose prefilled syringe may be stored at room temperature (up to 86Â°F (30Â°C)) for up to 30 days. When removed from the refrigerator and brought to room temperature VYVGART HYTRULO must be used within 30 days or thrown away. </item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>Single-dose vial may be stored at room temperature (between 68Â°F to 77Â°F (20Â°C to 25Â°C)) for up to 3 days. When removed from the refrigerator and brought to room temperature, VYVGART HYTRULO must be used within 3 days or thrown away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not put VYVGART HYTRULO back into the refrigerator after it has warmed to room temperature.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">Keep VYVGART HYTRULO and all medicines out of the reach of children</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">General information about the safe and effective use of VYVGART HYTRULO.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VYVGART HYTRULO for a condition for which it was not prescribed. Do not give VYVGART HYTRULO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VYVGART HYTRULO that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td/>
                           <td/>
                           <td/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What are the ingredients in VYVGART HYTRULO?<br/>Active ingredients:</content> efgartigimod alfa and hyaluronidase (human recombinant)<br/>
                              <content styleCode="bold">Inactive ingredients:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>single-dose prefilled syringe: arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, methionine, polysorbate 80, sodium chloride, sucrose, and water for injection, USP</item>
                                 <item>single-dose vial: histidine, L-histidine hydrochloride monohydrate, methionine, polysorbate 20, sodium chloride, sucrose and water for injection, USP</item>
                              </list>									Manufactured by: 									<list listType="unordered" styleCode="Disc">
                                 <item>argenx BV Industriepark 7, 9052 Zwijnaarde, Belgium, U.S. License No. 2217</item>
                                 <item>Halozyme, Inc. 12390 El Camino Real, San Diego, CA 92130, U.S. License No. 2187 </item>
                              </list>Distributed by: argenx US, Inc. 33 Arch Street, Boston, MA 02110<br/>VYVGART HYTRULO is a registered trademark of argenx BV.<br/>Â© 2025 argenx BV</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250416"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="b0e11f0f-e7fd-4d84-9fa9-fded86c0eaaf"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">VYVGART HYTRULO [viv' gart hye troo' loe]<br/>(efgartigimod alfa and hyaluronidase-qvfc)<br/>injection, for subcutaneous use<br/>1,000 mg and 10,000 units/5 mL</content>
                  </paragraph>
                  <paragraph>This Instructions for Use contains information on how to inject VYVGART HYTRULO.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information You Need to Know Before Injecting VYVGART HYTRULO</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">VYVGART HYTRULO is for under the skin (subcutaneous) injection only.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Be sure to read and understand this Instructions for Use before injecting VYVGART HYTRULO</content>. Your healthcare provider should show you or your caregiver how to prepare and inject VYVGART HYTRULO the correct way before using it for the first time. Ask your healthcare provider if you have any questions.</item>
                     <item>
                        <content styleCode="bold">The prefilled syringe is for one-time-use only</content> and cannot be reused.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use VYVGART HYTRULO if it has been at room temperature for longer than 30 days.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use the prefilled syringe if it is expired. </item>
                     <item>
                        <content styleCode="bold">Do not</content> use the prefilled syringe if it is cracked, broken, or damaged. Return damaged prefilled syringes to the specialty pharmacy.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use a prefilled syringe if the liquid medicine is discolored or contains particles. <content styleCode="bold">The liquid medicine should look</content> clear to yellowish in color. A little cloudiness is normal. </item>
                     <item>
                        <content styleCode="bold">Do not</content> shake the prefilled syringe.</item>
                     <item>You will need supplies that are not provided with VYVGART HYTRULO (see <linkHtml href="#figJ">Figure J</linkHtml>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storing VYVGART HYTRULO Prefilled Syringe</content>
                  </paragraph>
                  <table width="100%">
                     <col width="48%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Store VYVGART HYTRULO in the refrigerator</content> between 36Â°F to 46Â°F (2Â°C to 8Â°C) (see <linkHtml href="#figA">Figure A</linkHtml>). </item>
                                 <item>
                                    <content styleCode="bold">Keep the prefilled syringes in the original carton</content> to protect them from light until ready to use.</item>
                                 <item>
                                    <content styleCode="bold">Keep VYVGART HYTRULO and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM4" ID="figA"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule">
                              <content styleCode="bold">Do not</content> freeze the prefilled syringes or store them in direct sunlight.<br/>
                              <content styleCode="bold">Do not</content> use a prefilled syringe that has been frozen or left in direct sunlight.</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Prefilled Syringe Parts</content>
                  </paragraph>
                  <table width="100%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Safety Needle (not provided with VYVGART HYTRULO prefilled syringe)</content> that is 25G, 5/8 inch length, thin wall</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Gather and Check the Prefilled Syringe</content>
                  </paragraph>
                  <table width="100%">
                     <col width="48%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">1 Remove the carton from the refrigerator</content>
                           </td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">1.1</content> Remove the carton containing the prefilled syringe from the refrigerator (see <linkHtml href="#figC">Figure C</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM7" ID="figC"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">1.2</content> Remove 1 prefilled syringe from the carton (see <linkHtml href="#figD">Figure D</linkHtml>) and place any remaining prefilled syringes back into the refrigerator for later use.</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM8" ID="figD"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">1.3</content> Remove the prefilled syringe from the tray (see <linkHtml href="#figE">Figure E</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM9" ID="figE"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">2 Check the prefilled syringe before use</content>
                           </td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">2.1 Check</content> the expiration date on the prefilled syringe label (see <linkHtml href="#figF">Figure F</linkHtml>).</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM10" ID="figF"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> use the prefilled syringe if the expiration date has passed.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">2.2 Check</content> the condition of the prefilled syringe and the prefilled syringe cap (see <linkHtml href="#figG">Figure G</linkHtml>).</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM11" ID="figG"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule" colspan="2">
                              <content styleCode="bold">Do not</content> use the prefilled syringe if it is cracked, broken, damaged, or if the prefilled syringe cap is missing.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">2.3 Check</content> the appearance of the liquid medicine in the prefilled syringe (see <linkHtml href="#figH">Figure H</linkHtml>).<br/>
                              <content styleCode="bold">The liquid medicine should look</content> clear to yellowish in color. A little cloudiness is normal.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM12" ID="figH"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> use the prefilled syringe if the liquid medicine is discolored or contains particles.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Prepare for the Injection</content>
                  </paragraph>
                  <table width="100%">
                     <col width="48%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">3 Allow the prefilled syringe to warm to room temperature</content>
                           </td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">3.1</content> Place the prefilled syringe on a clean flat surface and <content styleCode="bold">let it sit for at least 30 minutes,</content> to allow it to warm to room temperature (see <linkHtml href="#figI">Figure I</linkHtml>).</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM13" ID="figI"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> attempt to warm the prefilled syringe in any other way.<br/>
                              <content styleCode="bold">Do not</content> use the VYVGART HYTRULO prefilled syringe if it has been at room temperature for longer than 30 days.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">4 Gather supplies and wash your hands</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">4.1</content> Gather the following supplies that are <content styleCode="bold">not provided</content> with the prefilled syringe (see <linkHtml href="#figJ">Figure J</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM14" ID="figJ"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">4.2</content> Wash your hands with soap and water (see <linkHtml href="#figK">Figure K</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM15" ID="figK"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">5 Snap off the prefilled syringe cap and attach the safety needle</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">5.1</content> Carefully open the safety needle package and remove the needle (see <linkHtml href="#figL">Figure L</linkHtml>). <br/>Throw away the packaging into household trash.</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM16" ID="figL"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">5.2 Bend the prefilled syringe cap</content> to one side to snap it off and remove it from the prefilled syringe (see <linkHtml href="#figM">Figure M</linkHtml>).<br/>Throw away the prefilled syringe cap into the household trash.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM17" ID="figM"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> touch the tip of the prefilled syringe after the prefilled syringe cap has been removed.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">5.3</content> Hold the prefilled syringe by the syringe body in one hand, and <content styleCode="bold">attach the safety needle to the prefilled syringe by twisting it</content> to the right (clockwise) until you feel resistance (see <linkHtml href="#figN">Figure N</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM18" ID="figN"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">The safety needle is now attached to the prefilled syringe (see <linkHtml href="#figO">Figure O</linkHtml>).</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM19" ID="figO"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">6 Choose and clean the injection site on the stomach (abdomen)</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">6.1 Choose an injection site on the stomach (abdomen)</content> at least 2 inches away from the belly button (navel) (see <linkHtml href="#figP">Figure P</linkHtml>). <br/>
                              <content styleCode="bold">Change</content> (rotate) the injection site the next time you inject VYVGART HYTRULO.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM20" ID="figP"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> inject into skin that is irritated, red, bruised, infected, or tender. <content styleCode="bold">Do not</content> inject into skin that is hard, scarred, or has moles. <br/>
                              <content styleCode="bold">Do not</content> inject into a vein. VYVGART HYTRULO is for under the skin (subcutaneous) injection only.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">6.2 Clean the chosen injection site</content> with an alcohol swab and let it air dry (see <linkHtml href="#figQ">Figure Q</linkHtml>).</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM21" ID="figQ"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> blow on or touch the injection site after it has been cleaned.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Inject VYVGART HYTRULO</content>
                  </paragraph>
                  <table width="100%">
                     <col width="48%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">7 Pull back the needle shield and remove the clear needle cap</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">7.1</content> Pull the needle shield back (see <linkHtml href="#figR">Figure R</linkHtml>).<br/>
                              <content styleCode="bold">Note:</content> The needle shield will be used after the injection to cover the needle and protect from needle-stick injuries.</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM22" ID="figR"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">7.2</content> Hold the prefilled syringe body and <content styleCode="bold">remove the clear needle cap by pulling it straight off</content> of the needle (see <linkHtml href="#figS">Figure S</linkHtml>).<br/>Throw away the clear needle cap into the household trash.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM23" ID="figS"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule" colspan="2">
                              <content styleCode="bold">Do not</content> recap the needle.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">8 Give the injection</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <content styleCode="bold">8.1 Pinch the cleaned injection site</content> (Figure T).</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM24" ID="figT"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">While pinching the skin, <content styleCode="bold">insert the needle at a 45 to 90 degree angle</content> all the way into the pinched skin (see <linkHtml href="#figU">Figure U</linkHtml>).<br/>
                              <content styleCode="bold">Then release the pinched skin.</content>
                           </td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM25" ID="figU"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> pinch the skin too tightly as this can cause bruising.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">8.2 Slowly press the thumb pad down</content> all the way until it stops to inject the liquid medicine (see <linkHtml href="#figV">Figure V</linkHtml>). <br/>
                              <content styleCode="bold">It will take about 20 to 30 seconds</content> to inject all of the liquid medicine. <br/>You will feel resistance as you press down. Inject more slowly in case there is discomfort.<br/>It is ok if you need to pause or change your grip during the injection.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM26" ID="figV"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> try to force the thumb pad down quickly as this will make the thumb pad harder to press.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <content styleCode="bold">8.3</content> After all the liquid medicine is injected, <content styleCode="bold">remove the needle from the skin</content> by pulling it straight out without changing the angle that it was inserted (see <linkHtml href="#figW">Figure W</linkHtml>).</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM27" ID="figW"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Throw away (dispose of) the Used Prefilled Syringe</content>
                  </paragraph>
                  <table width="100%">
                     <col width="48%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">9 Cover the needle and throw away the used prefilled syringe</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">9.1 Carefully push the needle shield over the needle</content> until it snaps into place and covers the needle (see <linkHtml href="#figX">Figure X</linkHtml>).<br/>This helps to prevent needle-stick injuries.</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM28" ID="figX"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> recap the needle using the clear needle cap. Only use the needle shield to cover the needle.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">9.2 Throw away</content> the used prefilled syringe, with the needle still attached<content styleCode="bold">, into an FDA-cleared sharps disposal container</content> right away after use (see <linkHtml href="#figY">Figure Y</linkHtml>).</td>
                           <td styleCode="Rrule Botrule" rowspan="2">
                              <renderMultiMedia referencedObject="MM29" ID="figY"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Do not</content> throw away (dispose of) loose needles and syringes in your household trash.</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">10 Treat the injection site</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule">
                              <content styleCode="bold">10.1</content> If there is a small amount of blood or liquid at the injection site, press a sterile gauze over the injection site until the bleeding stops (see <linkHtml href="#figZ">Figure Z</linkHtml>). <br/>If needed, you may apply a small adhesive bandage.</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM30" ID="figZ"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Additional Disposal Information</content>
                  </paragraph>
                  <table width="100%">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule">If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: 									<list listType="unordered" styleCode="disc">
                                 <item>made of a heavy-duty plastic,</item>
                                 <item>can be closed with a tight-fitting, puncture-resistant lid without sharps being able to come out,</item>
                                 <item>upright and stable during use,</item>
                                 <item>leak-resistant, and</item>
                                 <item>properly labeled to warn of hazardous waste inside the container.</item>
                              </list>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. <br/>For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.<br/>
                              <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.<br/>
                              <content styleCode="bold">Always keep the sharps disposal container out of the reach of children.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Additional Information</content>
                  </paragraph>
                  <table width="100%">
                     <col width="80%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left">This Instructions for Use has been approved by the U.S. Food and Drug Administration</td>
                           <td align="left">Issued: 4/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">For more information, go to www.vyvgart.com or call 1-833-898-4278. <br/>
                              <br/>Manufactured by: <br/>argenx BV<br/>Industriepark 7 <br/>9052 Zwijnaarde, Belgium <br/>U.S. License No. 2217<br/>
                              <br/>Halozyme, Inc. <br/>12390 El Camino Real<br/>San Diego, CA 92130<br/>U.S. License No. 2187<br/>
                              <br/>Distributed by: <br/>argenx US, Inc. <br/>33 Arch Street<br/>Boston, MA 02110 </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure E</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure F</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Figure G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Figure H</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Figure I</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Figure J</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Figure K</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Figure L</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Figure M</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Figure N</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Figure O</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>Figure P</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM21">
                     <text>Figure Q</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM22">
                     <text>Figure R</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM23">
                     <text>Figure S</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM24">
                     <text>Figure T</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM25">
                     <text>Figure U</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM26">
                     <text>Figure V</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM27">
                     <text>Figure W</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM28">
                     <text>Figure X</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM29">
                     <text>Figure Y</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM30">
                     <text>Figure Z</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="634bdf44-cd88-44f7-8436-dd6ced50a1c5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5.6 mL Vial Carton</title>
               <text>
                  <paragraph>NDC 73475-3102-3</paragraph>
                  <paragraph>VYVGART<sup>Â®</sup> Hytrulo<br/>(efgartigimod alfa and<br/> hyaluronidase-qvfc)</paragraph>
                  <paragraph>INJECTION</paragraph>
                  <paragraph>1,008 mg and 11,200 units/5.6 mL<br/>(180 mg and 2,000 units/mL)</paragraph>
                  <paragraph>For subcutaneous injection<br/>over 30 to 90 seconds</paragraph>
                  <paragraph>One single-dose vial</paragraph>
                  <paragraph>Discard unused portion</paragraph>
                  <paragraph>Must be administered by<br/>a healthcare provider</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM31"/>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <observationMedia ID="MM31">
                     <text>PRINCIPAL DISPLAY PANEL - 5.6 mL Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b1581991-34f4-4cd5-94e3-6ec3a213c1df"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mL Syringe Carton</title>
               <text>
                  <paragraph>NDC 73475-1221-1</paragraph>
                  <paragraph>VYVGART Hytrulo<sup>Â®</sup>
                     <br/>(efgartigimod alfa and hyaluronidase-qvfc)</paragraph>
                  <paragraph>INJECTION</paragraph>
                  <paragraph>1,000 mg and 10,000 units/5 mL<br/>(200 mg and 2,000 units/mL)</paragraph>
                  <paragraph>For subcutaneous injection over 20 to 30 seconds</paragraph>
                  <paragraph>One single-dose prefilled syringe</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM32"/>
               </text>
               <effectiveTime value="20250416"/>
               <component>
                  <observationMedia ID="MM32">
                     <text>PRINCIPAL DISPLAY PANEL - 5 mL Syringe Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vyvgart-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>